{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-294938","form_type":"8-K","ticker":null,"cik":"0001060736","company_name":"Seagen Inc.","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.079348+00:00","generated_at":"2026-06-07T12:30:40.980939+00:00","sec_items":["2.01","3.01","3.03","5.01","5.03","5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Pfizer completes $229.00/share acquisition of Seagen; Seagen delisted from Nasdaq","bullets":["Merger closed December 14, 2023; Seagen becomes wholly owned subsidiary of Pfizer.","Each Seagen common share converted into the right to receive $229.00 in cash.","Seagen common stock ceased trading and will be delisted from Nasdaq; Form 15 to be filed to suspend SEC reporting.","All prior directors and named executive officers (CEO, CFO, etc.) ceased; new directors and President appointed by Pfizer.","Seagen charter and bylaws amended and restated in connection with the merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-294938","json":"https://secwatch.observer/filing/0001193125-23-294938.json","markdown":"https://secwatch.observer/filing/0001193125-23-294938.md","text":"https://secwatch.observer/filing/0001193125-23-294938.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1060736/000119312523294938/0001193125-23-294938-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1060736/000119312523294938/d557257d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:30:40.980939+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"187d9e99ec","claim":"Jean I. Liu departed as Chief Legal Officer at Seagen Inc..","evidence_excerpt":"David R. Epstein, Todd E. Simpson, Roger Dansey, Jean I. Liu, Chip R. Romp and Vaughn B. Himes ceased to be the Chief Executive Officer, Chief Financial Officer, President, Research and Development, Chief Legal Officer, Executive Vice President, Commercial U.S. and Chief Technical Officer, respectively, of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1060736/000119312523294938/0001193125-23-294938-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Chief Legal Officer"}],"fact_type":"executive_change"},{"claim_id":"30c68f72b5","claim":"Vaughn B. Himes departed as Chief Technical Officer at Seagen Inc..","evidence_excerpt":"David R. Epstein, Todd E. Simpson, Roger Dansey, Jean I. Liu, Chip R. Romp and Vaughn B. Himes ceased to be the Chief Executive Officer, Chief Financial Officer, President, Research and Development, Chief Legal Officer, Executive Vice President, Commercial U.S. and Chief Technical Officer, respectively, of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1060736/000119312523294938/0001193125-23-294938-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Chief Technical Officer"}],"fact_type":"executive_change"},{"claim_id":"3ec30f727c","claim":"Todd E. Simpson departed as Chief Financial Officer at Seagen Inc..","evidence_excerpt":"David R. Epstein, Todd E. Simpson, Roger Dansey, Jean I. Liu, Chip R. Romp and Vaughn B. Himes ceased to be the Chief Executive Officer, Chief Financial Officer, President, Research and Development, Chief Legal Officer, Executive Vice President, Commercial U.S. and Chief Technical Officer, respectively, of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1060736/000119312523294938/0001193125-23-294938-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"639ad95147","claim":"Chip R. Romp departed as Executive Vice President, Commercial U.S. at Seagen Inc..","evidence_excerpt":"David R. Epstein, Todd E. Simpson, Roger Dansey, Jean I. Liu, Chip R. Romp and Vaughn B. Himes ceased to be the Chief Executive Officer, Chief Financial Officer, President, Research and Development, Chief Legal Officer, Executive Vice President, Commercial U.S. and Chief Technical Officer, respectively, of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1060736/000119312523294938/0001193125-23-294938-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Executive Vice President, Commercial U.S."}],"fact_type":"executive_change"},{"claim_id":"8927e13026","claim":"Alison O’Neill was appointed as Director at Seagen Inc..","evidence_excerpt":"At the Effective Time, Deborah Baron and Alison O’Neill, each a director of Merger Sub immediately prior to the Effective Time, became directors of the Surviving Corporation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1060736/000119312523294938/0001193125-23-294938-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"became"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9c8c4e21a1","claim":"Chris Boshoff was appointed as President at Seagen Inc..","evidence_excerpt":"Chris Boshoff became the President of the Surviving Corporation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1060736/000119312523294938/0001193125-23-294938-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"became"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"acaae1b3f9","claim":"Roger Dansey departed as President, Research and Development at Seagen Inc..","evidence_excerpt":"David R. Epstein, Todd E. Simpson, Roger Dansey, Jean I. Liu, Chip R. Romp and Vaughn B. Himes ceased to be the Chief Executive Officer, Chief Financial Officer, President, Research and Development, Chief Legal Officer, Executive Vice President, Commercial U.S. and Chief Technical Officer, respectively, of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1060736/000119312523294938/0001193125-23-294938-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"President, Research and Development"}],"fact_type":"executive_change"},{"claim_id":"e6f58c5bc6","claim":"Deborah Baron was appointed as Director at Seagen Inc..","evidence_excerpt":"At the Effective Time, Deborah Baron and Alison O’Neill, each a director of Merger Sub immediately prior to the Effective Time, became directors of the Surviving Corporation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1060736/000119312523294938/0001193125-23-294938-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"became"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ec7a0dabaa","claim":"David R. Epstein departed as Chief Executive Officer at Seagen Inc..","evidence_excerpt":"David R. Epstein, Todd E. Simpson, Roger Dansey, Jean I. Liu, Chip R. Romp and Vaughn B. Himes ceased to be the Chief Executive Officer, Chief Financial Officer, President, Research and Development, Chief Legal Officer, Executive Vice President, Commercial U.S. and Chief Technical Officer, respectively, of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1060736/000119312523294938/0001193125-23-294938-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c30610f53557285ba04717076f53a59c1bd28b59","claim":"Seagen Inc.: Merger resulted in amendment and restatement of certificate of incorporation and bylaws.","evidence_excerpt":"At the Effective Time, in accordance with the terms of the Merger Agreement, the Company’s certificate of incorporation and by-laws were amended and restated in their entirety.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1060736/000119312523294938/0001193125-23-294938-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"76ca98334115668f9aad900df9eb9664ec2025ac","claim":"Seagen Inc. underwent a change of control involving Pfizer Inc. for $229.00 per share (closed 2023-12-14).","evidence_excerpt":"the General Corporation Law of the State of Delaware with respect to such Common Shares) were converted into the right to receive (without interest) an amount in cash equal to $229.00 (the “ Merger Consideration ”). As a result of the consummation of the transactions contemplated by the Merger Agreement, the Company became a wholly owned subsidiary of Pfizer at","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1060736/000119312523294938/0001193125-23-294938-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Pfizer Inc."},{"label":"Consideration","value":"$229.00 per share"},{"label":"Closing","value":"2023-12-14"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}